Kiniksa Pharmaceuticals International (KNSA) Change in Accured Expenses (2021 - 2025)
Kiniksa Pharmaceuticals International's Change in Accured Expenses history spans 5 years, with the latest figure at $19.6 million for Q4 2025.
- For Q4 2025, Change in Accured Expenses rose 78.54% year-over-year to $19.6 million; the TTM value through Dec 2025 reached $37.5 million, down 14.25%, while the annual FY2025 figure was $37.5 million, 14.25% down from the prior year.
- Change in Accured Expenses reached $19.6 million in Q4 2025 per KNSA's latest filing, up from $8.4 million in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $19.6 million in Q4 2025 to a low of -$10.6 million in Q1 2023.
- Average Change in Accured Expenses over 5 years is $5.2 million, with a median of $4.7 million recorded in 2022.
- Peak YoY movement for Change in Accured Expenses: plummeted 456.87% in 2022, then surged 345.95% in 2023.
- A 5-year view of Change in Accured Expenses shows it stood at $10.0 million in 2021, then crashed by 137.74% to -$3.8 million in 2022, then soared by 239.44% to $5.3 million in 2023, then soared by 107.96% to $11.0 million in 2024, then soared by 78.54% to $19.6 million in 2025.
- Per Business Quant, the three most recent readings for KNSA's Change in Accured Expenses are $19.6 million (Q4 2025), $8.4 million (Q3 2025), and $13.1 million (Q2 2025).